-10%2c17-Dihydroxyestra-1%2c4-dien-3-one.svg) | |
| Clinical data | |
|---|---|
| Other names | DHED; Estradiol paraquinol; Estra-1,4-diene-10β,17β-diol-3-one |
| Routes of administration | By mouth[1] |
| Drug class | Estrogen |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H24O3 |
| Molar mass | 288.387 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
10β,17β-Dihydroxyestra-1,4-dien-3-one (DHED), also known asestradiol paraquinol, is anorally active,centrallyselectiveestrogen and abiosyntheticprodrug ofestradiol.[2][1][3][4]
Upon systemic administration, regardless ofroute of administration, DHED has been found to rapidly and selectively convert into estradiol in thebrain, whereas no such conversion occurs in the rest of the body.[2][1][3] Moreover, DHED itself possesses no estrogenic activity, requiringtransformation into estradiol for its estrogenicity.[2][1][3] As such, the drug shows selective estrogenic effects in the brain (e.g., alleviation ofhot flashes,neuroprotection) that are said to be identical to those of estradiol, whereas estrogenic effects elsewhere in the body are not observed.[2][1][3]
DHED has been proposed as a possible novel estrogenic treatment forneurological andpsychiatric conditions associated withhypoestrogenism (e.g.,menopausal hot flashes,depression,cognitive decline,Alzheimer's disease, andstroke) that uniquely lacks potentially detrimental estrogenicside effects in the periphery.[2][1][3]
